# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Absorption improvements appear to continue with DehydraTECH-processed Rybelsus® vs. Rybelsus® tablets even under "fed" ...
HC Wainwright & Co. analyst Yi Chen reiterates Lexaria Bioscience (NASDAQ:LEXX) with a Buy and maintains $10 price target.
- Reuters
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug d...
Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of ...
HC Wainwright & Co. analyst Yi Chen initiates coverage on Lexaria Bioscience (NASDAQ:LEXX) with a Buy rating and announc...